Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance

Dendritic cells (DCs) are well-established as major players in the regulation of immune responses. They either induce inflammatory or tolerogenic responses, depending on the DC-subtype and stimuli they receive from the local environment. This dual capacity of DCs has raised therapeutic interest for...

Full description

Bibliographic Details
Main Authors: Charlotte Castenmiller, Brigitte-Carole Keumatio-Doungtsop, Ronald van Ree, Esther C. de Jong, Yvette van Kooyk
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.643240/full
_version_ 1819168527378022400
author Charlotte Castenmiller
Brigitte-Carole Keumatio-Doungtsop
Ronald van Ree
Ronald van Ree
Esther C. de Jong
Yvette van Kooyk
author_facet Charlotte Castenmiller
Brigitte-Carole Keumatio-Doungtsop
Ronald van Ree
Ronald van Ree
Esther C. de Jong
Yvette van Kooyk
author_sort Charlotte Castenmiller
collection DOAJ
description Dendritic cells (DCs) are well-established as major players in the regulation of immune responses. They either induce inflammatory or tolerogenic responses, depending on the DC-subtype and stimuli they receive from the local environment. This dual capacity of DCs has raised therapeutic interest for their use to modify immune-activation via the generation of tolerogenic DCs (tolDCs). Several compounds such as vitamin D3, retinoic acid, dexamethasone, or IL-10 and TGF-β have shown potency in the induction of tolDCs. However, an increasing interest exists in defining tolerance inducing receptors on DCs for new targeting strategies aimed to develop tolerance inducing immunotherapies, on which we focus particular in this review. Ligation of specific cell surface molecules on DCs can result in antigen presentation to T cells in the presence of inhibitory costimulatory molecules and tolerogenic cytokines, giving rise to regulatory T cells. The combination of factors such as antigen structure and conformation, delivery method, and receptor specificity is of paramount importance. During the last decades, research provided many tools that can specifically target various receptors on DCs to induce a tolerogenic phenotype. Based on advances in the knowledge of pathogen recognition receptor expression profiles in human DC subsets, the most promising cell surface receptors that are currently being explored as possible targets for the induction of tolerance in DCs will be discussed. We also review the different strategies that are being tested to target DC receptors such as antigen-carbohydrate conjugates, antibody-antigen fusion proteins and antigen-adjuvant conjugates.
first_indexed 2024-12-22T19:05:01Z
format Article
id doaj.art-1c4e4b4e09454ba498a8ea8cd124b051
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-12-22T19:05:01Z
publishDate 2021-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-1c4e4b4e09454ba498a8ea8cd124b0512022-12-21T18:15:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-02-011210.3389/fimmu.2021.643240643240Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific ToleranceCharlotte Castenmiller0Brigitte-Carole Keumatio-Doungtsop1Ronald van Ree2Ronald van Ree3Esther C. de Jong4Yvette van Kooyk5Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, NetherlandsDepartment of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, Vrije Universiteit Amsterdam, Amsterdam, NetherlandsDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, NetherlandsDepartment of Otorhinolaryngology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, NetherlandsDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, NetherlandsDepartment of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, Vrije Universiteit Amsterdam, Amsterdam, NetherlandsDendritic cells (DCs) are well-established as major players in the regulation of immune responses. They either induce inflammatory or tolerogenic responses, depending on the DC-subtype and stimuli they receive from the local environment. This dual capacity of DCs has raised therapeutic interest for their use to modify immune-activation via the generation of tolerogenic DCs (tolDCs). Several compounds such as vitamin D3, retinoic acid, dexamethasone, or IL-10 and TGF-β have shown potency in the induction of tolDCs. However, an increasing interest exists in defining tolerance inducing receptors on DCs for new targeting strategies aimed to develop tolerance inducing immunotherapies, on which we focus particular in this review. Ligation of specific cell surface molecules on DCs can result in antigen presentation to T cells in the presence of inhibitory costimulatory molecules and tolerogenic cytokines, giving rise to regulatory T cells. The combination of factors such as antigen structure and conformation, delivery method, and receptor specificity is of paramount importance. During the last decades, research provided many tools that can specifically target various receptors on DCs to induce a tolerogenic phenotype. Based on advances in the knowledge of pathogen recognition receptor expression profiles in human DC subsets, the most promising cell surface receptors that are currently being explored as possible targets for the induction of tolerance in DCs will be discussed. We also review the different strategies that are being tested to target DC receptors such as antigen-carbohydrate conjugates, antibody-antigen fusion proteins and antigen-adjuvant conjugates.https://www.frontiersin.org/articles/10.3389/fimmu.2021.643240/fulldendritic celltoleranceimmunotherapysurface receptorsC-type lectinsSiglecs
spellingShingle Charlotte Castenmiller
Brigitte-Carole Keumatio-Doungtsop
Ronald van Ree
Ronald van Ree
Esther C. de Jong
Yvette van Kooyk
Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance
Frontiers in Immunology
dendritic cell
tolerance
immunotherapy
surface receptors
C-type lectins
Siglecs
title Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance
title_full Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance
title_fullStr Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance
title_full_unstemmed Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance
title_short Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance
title_sort tolerogenic immunotherapy targeting dc surface receptors to induce antigen specific tolerance
topic dendritic cell
tolerance
immunotherapy
surface receptors
C-type lectins
Siglecs
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.643240/full
work_keys_str_mv AT charlottecastenmiller tolerogenicimmunotherapytargetingdcsurfacereceptorstoinduceantigenspecifictolerance
AT brigittecarolekeumatiodoungtsop tolerogenicimmunotherapytargetingdcsurfacereceptorstoinduceantigenspecifictolerance
AT ronaldvanree tolerogenicimmunotherapytargetingdcsurfacereceptorstoinduceantigenspecifictolerance
AT ronaldvanree tolerogenicimmunotherapytargetingdcsurfacereceptorstoinduceantigenspecifictolerance
AT esthercdejong tolerogenicimmunotherapytargetingdcsurfacereceptorstoinduceantigenspecifictolerance
AT yvettevankooyk tolerogenicimmunotherapytargetingdcsurfacereceptorstoinduceantigenspecifictolerance